|Bid||3.2500 x 3000|
|Ask||3.3100 x 21500|
|Day's Range||3.1100 - 3.3300|
|52 Week Range||1.1700 - 3.4700|
|Beta (5Y Monthly)||1.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.00|
ADMA Biologics ( NASDAQ:ADMA ) Third Quarter 2022 Results Key Financial Results Revenue: US$41.1m (up 99% from 3Q...
Adma Biologics (ADMA) delivered earnings and revenue surprises of 0% and 18.86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
3Q2022 Total Revenues Were $41.1 Million, a 99% Y-o-Y Increase Grew 3Q2022 Gross Profit to $9.7 Million, a $9.3 Million Y-o-Y Increase Raising FY 2022 Total Revenue Guidance to $145 Million From $130 Million Previously Gross Profit Growth and Narrowing Net Losses Expected into 2023 Conference Call Scheduled for Today at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Nov. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharm